ALK (002940.SZ) Latest News & Headlines

Weekly Recap | Zai Lab +0.58%, most brokers rate it buy

Weekly Review·Sep 5 at 08:27 AM

- Zai Lab cumulative weekly stock price rose 0.58 % to close at 26.23 dollars, outperforming the S & P 500. - A total of 12 institutions provided ratings with a consensus target price of 33.14 dollars, reflecting a significant valuation divergence ranging from 24.25 dollars to 50.00 dollars. - The company released no new announcements during the week, while market focus centered on VYVGART Hytrulo product data and subsequent capital revaluation trends.

ZLAB-0.12%

Innovative drug concept repeatedly active, ALK straight to the daily limit, Rundu Pharma previously sealed the board, InventisBio, Junshi Biosciences, HWPC, and Biokin Pharmaceutical rose more than 6%

Wallstreetcn·Apr 1 at 02:07 AM

159892-1.69%516820-1.47%

The Shanghai Composite Index rose 1.22%, returning to 3,900 points, with nearly 4,400 stocks in the entire market rising

Wallstreetcn·Oct 15, 2025 at 07:06 AM

002050-1.66%002940-4.15%

The Shanghai Composite Index fluctuated and rose by 0.5%, with rare earth and lithium mining stocks collectively strengthening

Wallstreetcn·Jul 18, 2025 at 07:03 AM

688166-2.46%002940-4.15%

July 17th Midday Review: The ChiNext Index rose 1.13% in half a day, AI hardware stocks surged again

Wallstreetcn·Jul 17, 2025 at 03:31 AM

603716-2.96%300878-0.48%

June 10th Midday Review: Shanghai Composite Index fluctuates narrowly, up 0.11%, innovative drug concept continues to be strong

Wallstreetcn·Jun 10, 2025 at 03:31 AM

002940-4.15%002317-3.43%